# US 10,946,097 B2 · Fractionated radiotherapy and chemotherapy with an oxygen therapeutic

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,097 B2
- Document ID: US10946097B2
- Status: Granted
- Kind: B2
- Application number: 16/550,183
- Filed: 2019-08-24
- Published: 2020-02-20
- Granted: 2021-03-16
- Earliest claimed: 2014-03-05
- Assignees: NuvOx Pharma LLC
- Applicants: NuvOx Pharma LLC
- Inventors: Evan C. Unger
- Web page: https://patentgrep.com/patent/US10946097B2

## CPC

- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/02: Halogenated hydrocarbons
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.

## Claims

### Claim 1

A method of treating glioblastoma by multi-fraction radiotherapy or chemotherapy, comprising:
concomitantly or up to 120 minutes prior to each fraction of radiation therapy or concomitantly with chemotherapy, administering to a subject suffering from glioblastoma a water emulsion of perfluoropentane to the mammal, wherein the perfluoropentane emulsion comprises a viscosity modifier, a fluorosurfactant, and about 1% to 5% w/vol of perfluoropentane; and
simultaneously administering to said mammal carbogen or supplemental oxygen,
wherein the perfluoropentane emulsion is administered at a dosage in the range from about 0.05 cc/kg to about 0.3 cc/kg.

### Claim 2 (depends on 1)

The method of claim 1, wherein the perfluoropentane emulsion comprises about 2% w/vol of perfluoropentane.

### Claim 3 (depends on 1)

The method of claim 1, wherein administration of the perfluoropentane emulsion is intravenous infusion for up to 30 minutes.

### Claim 4 (depends on 1)

The method of claim 1, wherein administration of the perfluoropentane emulsion is intravenous infusion as a single bolus.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fluorosurfactant is PEG Telomer B.

### Claim 6 (depends on 5)

The method of claim 5, wherein said viscosity modifier comprises sucrose.

### Claim 7 (depends on 6)

The method of claim 6, wherein said sucrose is present at about 300 mg/mL.

### Claim 8 (depends on 5)

The method of claim 5, wherein said fluorosurfactant is PEG Telomer B is present at about 3 mg/mL.

### Claim 9 (depends on 1)

The method of claim 1, wherein the perfluoropentane emulsion is co-administered with an anticancer agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein said anticancer agent is an antibody.